There is no registration fee for this event. For the in-person symposium in Las Vegas, preregistration is required as seating is limited.
Faculty Daniel J George, MD
Eleanor Easley Distinguished Professor
Professor of Medicine, Urology and Surgery
Duke University School of Medicine
Divisions of Medical Oncology and Urology
Duke Cancer Institute
Durham, North Carolina
Leonard G Gomella, MD
The Bernard W Godwin Professor of Prostate Cancer
Chairman, Department of Urology
Senior Director Clinical Affairs Sidney Kimmel Cancer Center
Enterprise VP for Urology, Jefferson Health
Editor-in-Chief, Canadian Journal of Urology International
Thomas Jefferson University
Philadelphia, Pennsylvania
Moderator
To be announced.
This activity is supported by an educational grant from AstraZeneca Pharmaceuticals LP.
Program Schedule — Pacific Time
7:30 AM – 8:00 AM — Registration and Breakfast
8:00 AM – 9:30 AM — Educational Meeting
Topics to Be Discussed
Validated molecular biomarkers to aid in risk stratification and clinical decision-making in prostate cancer; current guideline-recommended approaches to bio-marker evaluation
Emerging clinical trial findings with capivasertib for PTEN-deficient metastatic hormone-sensitive prostate cancer (mHSPC) and the implications for biomarker evaluation; optimal timing and approach to PTEN testing
Biological justification for targeting the PI3K/AKT/mTOR pathway in prostate cancer, particularly in PTEN-deficient disease
Published findings from the Phase III IPATential150 trial evaluating the AKT inhibitor ipatasertib in combination with abiraterone/prednisolone for metastatic castration-resistant prostate cancer (mCRPC); correlation of PTEN status with outcomes
Pharmacologic similarities and differences between ipatasertib and capivasertib; implications for efficacy and tolerability
Design, eligibility criteria and emerging efficacy and safety results from the Phase III CAPItello-281 trial assessing capivasertib with abiraterone and androgen deprivation therapy (ADT) for patients with de novo mHSPC and PTEN deficiency
Design, eligibility criteria and primary and secondary endpoints of the ongoing Phase III CAPItello-280 trial evaluating capivasertib with docetaxel/ADT for patients with mCRPC; estimated completion date
Spectrum of toxicities associated with capivasertib; tolerability of this agent in combination with abiraterone/ADT
Target Audience
This activity has been designed to meet the educational needs of medical and radiation oncologists, urologists and other allied healthcare professionals involved in the treatment of prostate cancer.
Learning Objectives
Upon completion of this activity, participants should be able to
Appreciate the incidence and clinical relevance of PTEN deficiency in prostate cancer, and understand the optimal method for assessing PTEN status in patients.
Evaluate emerging Phase III data with combined AKT and androgen biosynthesis inhibition for patients with metastatic hormone-sensitive prostate cancer and PTEN deficiency, and consider the potential role of this form of therapy in the current treatment algorithm.
Implement a plan of care to recognize and manage side effects and toxicities associated with AKT inhibitors in preparation for their potential availability for patients with prostate cancer.
Recall the design of ongoing clinical trials evaluating novel AKT inhibitors in combination with standard therapies for metastatic prostate cancer, and appropriately counsel patients about availability and participation.
CME Credit Form
A CME credit link will be given to each participant as part of the meeting course materials.
Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Unlabeled/Unapproved Uses Notice
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantor.
Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
FACULTY To be announced.
MODERATOR To be announced.
RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
Supporters
This activity is supported by an educational grant from AstraZeneca Pharmaceuticals LP.
The Venetian Las Vegas
3355 S Las Vegas Blvd
Las Vegas, NV 89109
Hotel Phone: (702) 414-1000
Directions
The Venetian Las Vegas is the main venue for the AUA Annual Meeting 2025.
This activity has been designed to meet the educational needs of medical and radiation oncologists, urologists and other allied healthcare professionals involved in the treatment of prostate cancer.
There is no registration fee for this event. For the in-person symposium in Las Vegas, preregistration is required as seating is limited.
NOTICE: Registration for this event is independent of registration for AUA2025.
IN-PERSON Registration for clinicians in practice/healthcare professionals
I am a practicing physician, fellow, nurse or other healthcare provider involved in the treatment of cancer.
If you are registering a group (more than 1 person) for this event, please contact us at
Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk before the start of the meeting. We cannot guarantee seating after the start of the program.
Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.
Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.
